7.11
Spasmolytic Agents: Chemical Classification
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mec…
Spasmolytics are drugs that relieve spasticity, a condition marked by involuntary muscle contractions, muscle stiffness, weakness and painful muscle spasms.
Some spasmolytics are centrally acting and affect the spinal cord, while others are direct agents that work on the skeletal muscle cells.
Chemically, centrally acting spasmolytics can be of three types.
An ɑ2-agonist like tizanidine binds the ɑ2-adrenoceptor and inhibits the release of the excitatory neurotransmitter glutamate. It also promotes the release of glycine, which causes an influx of chloride into postsynaptic neurons, and reduces their excitability.
Ɣ aminobutyric acid or GABA mimetics like baclofen activate the GABAB receptors, inducing hyperpolarization of neuronal membranes and reducing their excitability.
They also inhibit the release of excitatory neurotransmitters and inactivate sensory, motor and interneurons.
The last group of spasmolytics includes the benzodiazepines such as diazepam, which binds the allosteric site of GABAA receptors and causes an influx of chloride ions, hyperpolarizing the membrane to inhibit neurotransmission.
View the full transcript and gain access to JoVE Core videos
Q1: What are spasmolytics and what conditions do they treat?
Spasmolytics are drugs that relieve spasticity, a condition characterized by involuntary muscle contractions, muscle stiffness, weakness, and painful muscle spasms. These agents work through different mechanisms: some are centrally acting and affect the spinal cord, while others are direct agents that work on skeletal muscle cells themselves.
Q2: How do alpha-2 agonists like tizanidine reduce muscle spasticity?
Alpha-2 agonists such as tizanidine bind to alpha-2-adrenoceptors and inhibit the release of glutamate, an excitatory neurotransmitter. They also promote glycine release, which causes chloride influx into postsynaptic neurons, reducing their excitability. This dual mechanism provides potent suppression of spasticity through complementary inhibitory pathways.
Q3: What is the mechanism of action for GABA mimetics like baclofen?
GABA mimetics such as baclofen activate GABAB receptors, inducing hyperpolarization of neuronal membranes and reducing their excitability. They also inhibit the release of excitatory neurotransmitters and inactivate sensory, motor, and interneurons in the brain and spinal cord, suppressing muscle spasticity.
Q4: How do benzodiazepines like diazepam work as spasmolytics?
Benzodiazepines such as diazepam bind to the allosteric site of GABAA receptors, facilitating chloride ion influx into neurons. This hyperpolarizes the neuronal membrane and inhibits neurotransmission, reducing spasticity particularly in the spinal cord. However, sedation can occur at doses required to reduce muscle tone.
Q5: What are the three chemical classes of centrally acting spasmolytics?
Centrally acting spasmolytics fall into three chemical classes: alpha-2 agonists like tizanidine, GABA mimetics like baclofen, and benzodiazepines like diazepam. Each class targets different receptors and neurotransmitter systems in the central nervous system to reduce muscle excitability and spasticity through distinct mechanisms.
Q6: How do centrally acting spasmolytics differ from direct-acting agents?
Centrally acting spasmolytics affect the spinal cord by modulating neurotransmitter release and neuronal excitability, while directly acting muscle relaxants work on skeletal muscle cells themselves. This distinction in site of action determines their therapeutic profiles and potential side effects in treating muscle spasticity.
Q7: Why do alpha-2 agonists promote both glutamate inhibition and glycine release?
Alpha-2 agonists like tizanidine use a dual mechanism to reduce neuronal excitability: they inhibit glutamate release, removing excitatory signaling, while simultaneously promoting glycine release, which enhances inhibitory chloride influx into postsynaptic neurons. This combined action provides potent suppression of spasticity through complementary inhibitory pathways.